Skip to main content

Resmed Inc

RSMDF
Exchange
OTC
Industry
Surgical & Medical Instruments & Apparatus
SEC CIK
0000943819

In the last 90 days, Resmed Inc insiders filed 0 open-market purchases and 5 sales; 1 institution reported holding it in 13F filings for Q2 2026, worth $1.17K in total; no superinvestor holds it.

Other share classesRMD

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Resmed Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
5 filings
2 insiders, $5.26M in total
Insiders trading
2
Net value
−$5.26M
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Resmed Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Resmed Inc
NameTitleLast reported holdingLast filingFilings, past year
Farrell Michael J.Chairman and CEO466,256Sep 10, 202615
Farrell Peter CDirector51,803Sep 4, 202611
Rider Michael JGlobal General Counsel9,488Jun 3, 20266
Sandercock BrettChief Financial Officer83,495May 4, 20269
De Witte JanDirector4,261Nov 26, 20253
Mowad-Nassar NicoleDirector777Nov 26, 20252
Taylor Ronald RDirector24,771Nov 24, 20251
Burt CarolDirector2,156Nov 24, 20251
Drexler KarenDirector10,602Nov 24, 20251
Gill HarjitDirector10,940Nov 24, 20252
Leong JustinChief Product Officer29,028Nov 24, 20251
DelOrefice ChristopherDirector2,423Nov 24, 20251
Tan DesneyDirector6,002Nov 24, 20251
Hernandez JohnDirector5,118Nov 24, 20251
Sulpizio RichardDirector17,796Nov 21, 20251
Ghoshal KaushikChief Commercial Officer, SaaS9,725Aug 5, 20250
Douglas Robert AndrewSpecial Advisor13,849Jan 3, 20240
Blaise LucilePresident, Sleep & RC Business10,305Nov 16, 20230
Pendarvis DavidChief Administrative Officer89,729Jun 30, 20230
Hollingshead JamesPresident, Sleep Business76,721Dec 1, 20210
Resmed IncDirector13,823Nov 22, 20210
Sodhi RajwantPresident, SaaS Business26,731Oct 14, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
May 8, 2025 (view filing)May 71 dayFarrell Peter CDirectorSSaleResMed Common Stock−2.00K$242.25−$484.5K−2.7%71.2K after10b5-1
Apr 10, 2025 (view filing)Apr 82 daysSandercock BrettChief Financial OfficerSSaleResMed Common Stock−1.00K$215.58−$215.6K−1.1%89.9K after10b5-1
Apr 9, 2025 (view filing)Apr 72 daysFarrell Michael J.Chief Executive OfficerSSaleResMed Common Stock−8.01K$209.85−$1.68M−1.7%455.5K after10b5-1
Apr 4, 2025 (view filing)Apr 22 daysFarrell Peter CDirectorSSaleResMed Common Stock−2.00K$219.74−$439.5K−2.7%73.2K after10b5-1
Apr 3, 2025 (view filing)Apr 12 daysRider Michael JGlobal General CounselSSaleResMed Common Stock−64$222.86−$14.3K−0.7%8.85K after10b5-1
Mar 11, 2025 (view filing)Mar 101 daySandercock BrettChief Financial OfficerSSaleResMed Common Stock−1.00K$230.36−$230.4K−1.1%90.9K after10b5-1
Mar 11, 2025 (view filing)Mar 101 dayGhoshal KaushikChief Commercial Officer, SaaSSSaleResMed Common Stock−9.74K$239.31−$2.33M−50.1%9.72K after10b5-1
Mar 11, 2025 (view filing)Mar 74 daysFarrell Michael J.Chief Executive OfficerSSaleResMed Common Stock−8.01K$229.20−$1.84M−1.7%455.5K after10b5-1
Mar 6, 2025 (view filing)Mar 51 dayFarrell Peter CDirectorSSaleResMed Common Stock−2.00K$227.71−$455.4K−2.6%75.2K after10b5-1
Mar 4, 2025 (view filing)Mar 31 dayGhoshal KaushikChief Commercial Officer, SaaSSSaleResMed Common Stock−9.11K$235.40−$2.15M−48.4%9.72K after4 lots10b5-1
Mar 4, 2025 (view filing)Mar 31 dayRider Michael JGlobal General CounselSSaleResMed Common Stock−64$234.10−$15.0K−0.7%8.91K after10b5-1
Feb 11, 2025 (view filing)Feb 101 daySandercock BrettChief Financial OfficerSSaleResMed Common Stock−1.00K$238.98−$239.0K−1.1%91.9K after10b5-1
Feb 11, 2025 (view filing)Feb 74 daysFarrell Michael J.Chief Executive OfficerSSaleResMed Common Stock−8.01K$236.77−$1.90M−1.7%455.5K after10b5-1
Feb 5, 2025 (view filing)Feb 5Same dayFarrell Peter CDirectorSSaleResMed Common Stock−2.00K$242.11−$484.2K−2.5%77.2K after10b5-1
Feb 4, 2025 (view filing)Feb 31 dayRider Michael JGlobal General CounselSSaleResMed Common Stock−64$242.42−$15.5K−0.7%8.97K after10b5-1
Jan 10, 2025 (view filing)Jan 82 daysSandercock BrettChief Financial OfficerSSaleResMed Common Stock−1.00K$234.04−$234.0K−1.1%92.9K after10b5-1
Jan 3, 2025 (view filing)Jan 21 dayFarrell Peter CDirectorSSaleResMed Common Stock−2.00K$230.99−$462.0K−2.5%79.2K after10b5-1
Jan 3, 2025 (view filing)Jan 21 dayRider Michael JGlobal General CounselSSaleResMed Common Stock−75$230.99−$17.3K−0.8%9.04K after10b5-1
Dec 11, 2024 (view filing)Dec 92 daysSandercock BrettChief Financial OfficerSSaleResMed Common Stock−1.00K$244.23−$244.2K−1.1%93.9K after10b5-1
Dec 5, 2024 (view filing)Dec 41 dayFarrell Peter CDirectorSSaleResMed Common Stock−2.00K$245.65−$491.3K−2.4%81.2K after10b5-1
Dec 2, 2024 (view filing)Dec 2Same dayRider Michael JGlobal General CounselSSaleResMed Common Stock−74$248.91−$18.4K−0.8%9.11K after10b5-1
Nov 27, 2024 (view filing)Nov 27Same dayFarrell Michael J.Chief Executive OfficerSSaleResMed Common Stock−2.00K$249.67−$499.3K−100.0%0 after
Nov 25, 2024 (view filing)Nov 223 daysLeong JustinChief Product OfficerSSaleReMed Common Stock−6.16K$243.09−$1.50M−22.1%21.7K after
Nov 14, 2024 (view filing)Nov 122 daysDe Witte JanDirectorSSaleReMed Common Stock−796$248.81−$198.1K−10.6%6.72K after10b5-1
Nov 12, 2024 (view filing)Nov 75 daysFarrell Michael J.Chief Executive OfficerSSaleResMed Common Stock−14.7K$246.26−$3.62M−3.1%464.3K after10b5-1
Nov 12, 2024 (view filing)Nov 84 daysSandercock BrettChief Financial OfficerSSaleResMed Common Stock−1.00K$249.00−$249.0K−1.0%94.9K after10b5-1
Nov 8, 2024 (view filing)Nov 62 daysFarrell Peter CDirectorSSaleResMed Common Stock−2.00K$248.74−$497.5K−2.3%83.2K after10b5-1
Nov 5, 2024 (view filing)Nov 14 daysRider Michael JGlobal General CounselSSaleResMed Common Stock−69$242.00−$16.7K−0.7%10.4K after10b5-1
Oct 15, 2024 (view filing)Oct 114 daysGhoshal KaushikChief Commercial Officer, SaaSSSaleResMed Common Stock−4.26K$238.48−$1.02M−16.4%21.8K after10b5-1
Oct 9, 2024 (view filing)Oct 81 daySandercock BrettChief Financial OfficerSSaleResMed Common Stock−1.00K$233.47−$233.5K−1.0%95.8K after10b5-1
Oct 9, 2024 (view filing)Oct 72 daysFarrell Michael J.Chief Executive OfficerSSaleResMed Common Stock−14.7K$231.91−$3.41M−3.1%464.2K after10b5-1
Oct 2, 2024 (view filing)Oct 2Same dayFarrell Peter CDirectorSSaleResMed Common Stock−2.00K$237.20−$474.4K−2.3%85.2K after10b5-1
Sep 13, 2024 (view filing)Sep 121 dayGhoshal KaushikChief Commercial Officer, SaaSSSaleResMed Common Stock−5.00K$252.56−$1.26M−18.7%21.8K after10b5-1
Sep 10, 2024 (view filing)Sep 91 daySandercock BrettChief Financial OfficerSSaleResMed Common Stock−1.00K$246.42−$246.4K−1.0%96.8K after10b5-1
Sep 10, 2024 (view filing)Sep 91 dayFarrell Michael J.Chief Executive OfficerSSaleResMed Common Stock−14.7K$248.38−$3.65M−3.1%464.2K after10b5-1
Sep 6, 2024 (view filing)Sep 42 daysFarrell Peter CDirectorSSaleResMed Common Stock−2.00K$239.90−$479.8K−2.2%87.2K after10b5-1
Aug 21, 2024 (view filing)Aug 201 dayRider Michael JGlobal General CounselSSaleResMed Common Stock−882$231.00−$203.7K−7.7%10.5K after10b5-1
Aug 13, 2024 (view filing)Aug 121 dayGhoshal KaushikPresident, SaaS BusinessSSaleResMed Common Stock−10.0K$216.60−$2.17M−43.4%13.0K after10b5-1
Aug 12, 2024 (view filing)Aug 84 daysSandercock BrettChief Financial OfficerSSaleResMed Common Stock−1.00K$212.16−$212.2K−1.1%89.1K after10b5-1
Aug 9, 2024 (view filing)Aug 72 daysFarrell Michael J.Chief Executive OfficerSSaleResMed Common Stock−14.7K$214.25−$3.15M−3.2%440.8K after10b5-1
Aug 6, 2024 (view filing)Aug 51 dayLeong JustinPresident, Asia Latin AmericaSSaleReMed Common Stock−48.0K$217.07−$10.4M−71.9%18.7K after
Jul 10, 2024 (view filing)Jul 82 daysFarrell Michael J.Chief Executive OfficerSSaleResMed Common Stock−14.7K$192.97−$2.83M−3.2%440.8K after10b5-1
Jul 9, 2024 (view filing)Jul 81 daySandercock BrettChief Financial OfficerSSaleResMed Common Stock−1.00K$194.35−$194.3K−1.1%90.1K after10b5-1
Jun 11, 2024 (view filing)Jun 101 daySandercock BrettChief Financial OfficerSSaleResMed Common Stock−1.00K$209.81−$209.8K−1.1%91.1K after10b5-1
Jun 10, 2024 (view filing)Jun 73 daysFarrell Michael J.Chief Executive OfficerSSaleResMed Common Stock−14.7K$211.66−$3.11M−3.2%440.8K after10b5-1
May 22, 2024 (view filing)May 157 daysDe Witte JanDirectorSSaleReMed Common Stock−360$218.29−$78.6K−4.6%7.52K afterAmended10b5-1
May 10, 2024 (view filing)May 82 daysSandercock BrettChief Financial OfficerSSaleResMed Common Stock−13.0K$211.37−$2.75M−12.4%92.1K after10b5-1
May 9, 2024 (view filing)May 72 daysFarrell Michael J.Chief Executive OfficerSSaleResMed Common Stock−14.7K$216.50−$3.18M−3.2%440.8K after10b5-1
Apr 30, 2024 (view filing)Apr 291 dayDrexler KarenDirectorSSaleResMed Common Stock−425$214.92−$91.3K−4.8%8.45K after
Mar 6, 2024 (view filing)Mar 42 daysRider Michael JGlobal General CounselSSaleResMed Common Stock−81$180.00−$14.6K−1.2%6.61K after10b5-1